The beneficial effect of OST-6 (OsteoCare), a herbomineral formulation, in experimental osteoporosis

被引:12
作者
Mitra, SK [1 ]
Venkataranganna, MV
Udupa, UV
Gopumadhavan, S
Seshadri, SJ
Rafiq, M
Anturlikar, SD
Sundaram, R
Tripathi, M
机构
[1] Himalaya Drug Co, R&D Ctr, Res & Tech Serv, Dept Pharmacol, Makali 562123, Bangalore, India
[2] Himalaya Drug Co, R&D Ctr, Dept Toxicol & Histopathol, Makali 562123, Bangalore, India
[3] Himalaya Drug Co, R&D Ctr, Dept Analyt Chem, Makali 562123, Bangalore, India
关键词
osteoporosis; herbomineral formulation; OST-6 (OsteoCare); bone histomorphometry; osteoclasts; pyridinium cross-links;
D O I
10.1078/0944-7113-00034
中图分类号
Q94 [植物学];
学科分类号
071001 [植物学];
摘要
OST-6 (OsteoCare), a herbomineral formulation, was evaluated for its inhibitory effect on the progress of bone loss induced by ovariectomy in rats. Ovariectomized (Ovx) rats were administered with OST-6 at 250 and 500 mg/kg b.wt., orally daily for 90 days. On 91(st) day, ovariectomized rats showed reduced bone mineral content and increased serum alkaline phosphatase levels, excretion of urinary calcium and pyridinium cross-links levels, Histologically, bone sections revealed narrowed and disappearance of trabeculae and widened medullary spaces. The total numbers of Tartrate-resistant acid phosphatase (TRAP) positive cells were significantly increased both invivo and in-vitro methods. OST-6, at a dose of 500 mg/kg, significantly improved bone mineral contents, serum alkaline phosphatase levels, reduced the elevated urinary calcium and pyridinium cross-links excretion, number of TRAP positive cells and reversal of the above mentioned histological features, These results indicate the usefulness of OST-6 in the management of osteoporosis in a natural way through herbal resources.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 27 条
[1]
DETERMINATION OF PYRIDINIUM CROSS-LINKS IN PLASMA AND SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
ABBIATI, G ;
RIGOLDI, M ;
FRIGNANI, S ;
COLOMBO, L ;
MUSSINI, E .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 656 (02) :303-310
[2]
BANCROFT JD, 1988, MANUAL HISTOLOGICAL, P243
[3]
Importance of preclinical studies in the development of drugs for treatment of osteoporosis: A review related to the 1998 WHO guidelines [J].
Bonjour, JP ;
Ammann, P ;
Rizzoli, R .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (05) :379-393
[4]
RADIOCHEMICAL DETERMINATION OF THE METABOLIC-ACTIVITY OF COLLAGEN IN MATURE DENTIN [J].
BORGGREVEN, JMPM ;
HOPPENBROUWERS, PMM ;
GORISSEN, R .
JOURNAL OF DENTAL RESEARCH, 1979, 58 (11) :2120-2124
[5]
Drury RAB, 1980, H M CARLETONS HISTOL, V5th, P199
[6]
LONG-TERM ESTROGEN REPLACEMENT THERAPY PREVENTS BONE LOSS AND FRACTURES [J].
ETTINGER, B ;
GENANT, HK ;
CANN, CE .
ANNALS OF INTERNAL MEDICINE, 1985, 102 (03) :319-324
[7]
NEW BIOMARKERS OF BONE-RESORPTION [J].
EYRE, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) :A470-A470
[8]
HORN DB, 1972, CLIN CHIM ACTA, V37, P43, DOI 10.1016/0009-8981(72)90413-5
[9]
JOSHI SR, 1997, IND PRACTIT, V50, P254
[10]
THE AGED RAT MODEL OF OVARIAN HORMONE DEFICIENCY BONE LOSS [J].
KALU, DN ;
LIU, CC ;
HARDIN, RR ;
HOLLIS, BW .
ENDOCRINOLOGY, 1989, 124 (01) :7-16